C3 Peptide Promotes Axonal Regeneration and Functional Motor Recovery after Peripheral Nerve Injury by Huelsenbeck, Stefanie C. et al.
ORIGINAL ARTICLE
C3 Peptide Promotes Axonal Regeneration and Functional
Motor Recovery after Peripheral Nerve Injury
Stefanie C. Huelsenbeck & Astrid Rohrbeck & Annelie Handreck & Gesa Hellmich &
Eghlima Kiaei & Irene Roettinger & Claudia Grothe & Ingo Just & Kirsten Haastert-Talini
Published online: 25 August 2011
# The Author(s) 2011. This article is published with open access at Springerlink.com
Abstract Peripheral nerve injuries are frequently seen in
trauma patients and due to delayed nerve repair, lifelong
disabilities often follow this type of injury. Innovative
therapies are needed to facilitate and expedite peripheral
nerve regeneration. The purpose of this study was to determine
the effects of a 1-time topical application of a 26-amino-acid
fragment (C3
156-181), derived from the Clostridium botulinum
C3-exoenzyme, on peripheral nerve regeneration in 2 models
of nerve injury and repair in adult rats. After sciatic nerve
crush, different dosages of C3
156-181 dissolved in buffer or
reference solutions (nerve growth factor or C3
bot-wild-type
protein) or vehicle-only were injected through an epineurial
opening into the lesion sites. After 10-mm nerve autotrans-
plantation, either 8.0 nmol/kg C3
156-181 or vehicle were
injected into the proximal and distal suture sites. For a period
of 3 to 10 postoperative weeks, C3
156-181-treated animals
showed a faster motor recovery than control animals. After
crush injury, axonal outgrowth and elongation were activated
and consequently resulted in faster motor recovery. The nerve
autotransplantation model further elucidated that C3
156-181
treatment accounts for better axonal elongation into motor
targets and reduced axonal sprouting, which are followed by
enhanced axonal maturation and better axonal functionality.
The effects of C3
156-181 are likely caused by a nonenzymatic
down-regulation of active RhoA. Our results indicate the
potential of C3
156-181 as a therapeutic agent for the topical
treatment of peripheral nerve repair sites.
Keywords Sciatic nerve.Crush injury.10-mm nerve gap.
Autotransplantation.C3
156-181 peptide
Introduction
Peripheral nerve injuries affect 2.8% of trauma patients who
often acquire lifelong disability [1]. The annual incidence of
peripheral nerve injuries ranges from 13.9 in 100,000 inhab-
itants in Sweden [2] to 300,000 cases in Europe [3].
Regeneration of peripheral nerves after different types of
injury is generally possible, but the degree of recovery of
peripheral sensory and motor functions depends on the type of
the lesion and the distance across which the severed axons
must grow to re-innervate their distal targets [4, 5]. Insufficient
functional recovery is presumably related to at first variable
time points after nerve transection at which axonal sprouts
begin to elongate (“staggered outgrowth”)[ 6] and at second to
re-innervation of inappropriate pathways [7]. After nerve
crush injury, the continuity of the endoneurial tubes is
preserved and usually allows high degrees of functional
recovery [8]. Neurosurgical intervention is needed, when
complete nerve transection or even gaps between separated
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sensory nerve trunks is the clinical gold standard to overcome
larger nerve gaps (20 mm in humans), but this technique also
cannot ensure the recovery of normal sensorimotor functions
in adult patients [10]. The results achieved with nerve
autografting are variable, ranging from extremely poor [11],
including paresthesia and uncoordinated muscle contraction
[12], to very good [13]. Innovative concepts for therapeutic
interventions, therefore, are needed [4].
One concept is the transplantation of glia cells because the
success of nerve autotransplantation is mainly attributed to the
presence of Schwann cells [4]. The beneficial effects of
transplanted glia cells (Schwann cells and olfactory ensheath-
ing cells) have been clearly demonstrated in several animal
studies [14–17]. Donor Schwann cells do integrate with the
host tissue and contribute to the myelination of regenerated
axons and the formation of adequately reconstituted nodes of
Ranvier et al. [15]. Nearly the same behavior was demonstrated
for transplanted olfactory ensheathing cells, which also
accounted for increased functional recovery [14]. However,
extensive studies also demonstrate that transplantation of
primary or genetically modified glia cells alone are not
sufficient to guarantee complete recovery from severe periph-
eral nerve injuries [18–21]. Therefore, other innovative stand-
alone or combined therapeutic approaches are of high interest.
The administration of therapeutic agents from bacterial
origin could be such an innovative approach. Botulinum
neurotoxin, for example, has become a valid tool in the
treatment of neurological diseases related to different types of
spasm [22]. Clostridial C3 exoenzyme has been demonstrated
to promote axonal repair mechanisms after spinal cord injury
[23] and it has recently been demonstrated that intrathecal
treatment with a 29-amino-acid fragment (C3
154-182)d e r i v e d
from full-length Clostridium botulinum C3 exoenzyme
(C3
bot), improves axonal and functional recovery after spinal
cord contusion or hemisection injury [24].
Here we tested the effect of the shortest active peptide
derivedfrom C3
bot, the 26-amino-acid fragment, C3
156-181,o n
peripheral nerve regeneration. We used established paradigms
of sciatic nerve injury and repair in adult rats [18, 21, 25],
which enable functional, as well as histomorphological
evaluation of regeneration. Our results indicate that C3
156-181
promotes axonal elongation, maturation, and functional motor
recovery after peripheral nerve injury and repair.
Methods
C3
bot Purification and C3
156-181 Synthesis
C3
156-181 was synthesized at IPF PharmaCeuticals GmbH
(Hannover, Germany). The lyophilized peptide was recon-
stituted in phosphate buffered saline (PBS) (137 mM NaCl,
3 mM KCl, 6.6 mM Na2HPO4,1.5 mM KH2PO4, pH 7.5),
sterile filtered (0.22 μm), and used for the experiments as
indicated as follows.
C3
bot was expressed as recombinant GST-fusion protein
expressed in Escherichia coli using the pGEX-2T vector
system and purified by affinity chromatography using
glutathione-sepharose. C3
bot was mobilized from the
glutathione-sepharose by thrombin digest.
Experimental Design
Animals and Surgical Procedures
Animal experiments were conducted in accordance with
the German law on the protection of animals (approved
by the Animal Care Committee of Lower-Saxony: 33H-
42502-08/1564+09/1641).
Adult female Sprague-Dawley rats (200 g, 8 weeks
[Charles River, Sulzfeld, Germany]) were housed in groups
of 4 rats in Makrolon type IV cages (Ebeco, Castrop-
Rauxel, Germany) under standard conditions (room tem-
perature 22±2°C, humidity 55±5%, light/dark-cycle 14:10)
with food and water ad libitum.
Unilateral sciatic nerve lesionand repair were performedon
consecutive days, and on each day animals of all experimental
groups underwent surgery.
Animals were anesthetized by intraperitoneal injection of
chloral hydrate (370 mg/kg body weight; Sigma-Aldrich
Chemie GmbH, Steinheim, Germany). To achieve sufficient
analgesia, buprenorphine (0.045 mg/kg body weight,
Temgesic; Essex Pharma GmbH, Munic, Germany) was
intramuscularly applied. Body temperature was monitored and
animals were kept on an electric heating pad during anesthesia.
The left hind legs were shaved, the skin disinfected, and aseptic
techniques used to ensure sterility. The left sciatic nerve was
exposed by a skin incision along the femur followed by blunt
separationofthebicepsfemorisandsuperficialglutealmuscles.
The nerve was freed from surrounding connective tissue.
The 2 different sciatic nerve injury and repair models used in
this study are depicted in Fig. 1. For nerve crush (crush, n=10)
the sciatic nerve was crushed 3 times, for 5 seconds each, using
No.5 Dumont forceps (Fine Science Tools GmbH, Heidelberg,
Germany). Afterward, an epineurial window was opened at the
lesion site using microscissors (Vannas-Tübingen; Fine Science
Tools GmbH, Heidelberg, Germany). Through the incision, the
cone tip of a fixed needle plunger protection syringe (26-
gauge, SGE GmbH, Griesheim, Germany) was inserted and a
2×20 μLo fC 3
156-181 peptide solution or solutions of nerve
growth factor (NGF) (reference group 1; Sigma-Aldrich,
Taufkirchen, Germany) or C3
bot-wild-type protein (reference
group 2) or of vehicle alone (vehicle control, PBS) injected
directly into the crush lesion. The epineurial window was
closed with a single epineurial suture (9–0 Ethilon II; Ethicon,
186 Huelsenbeck et al.Norderstedt, Germany). The final treatment dosage was as
follows: C3
156-181 peptide: 1.6 nmol/kg body weight, 8 nmol/
kg body weight, or 40 nmol/kg body weight; NGF: 5 mg/kg
body weight; C3
bot-wild-type protein: 8 nmol/kg body weight.
For nerve reconstruction using nerve autotransplantation,
thesciaticnervewastransectedproximaltoitstrifurcationinto
the tibialnerve,the commonfibular, and the sural nerve.After
reconnectionwithepineurialsutures (9–0 Ethilon II; Ethicon),
the nerve was transected and sutured 10-mm distal to the first
transection site again. Into each suture site, 20 μL of 8 nmol/
kg body weight C3
156-181 peptide or vehicle (PBS) were
injected, and the sutures covered each with a small strip of
absorbable gelatin sponge (Equispon; Equimedical BV,
Zwanenburg, The Netherlands) to avoid leakage.
Finally, muscle layers (4–0 Ethilon II) and the skin were
sutured (3–0 Dexon; Braun-Dexon GmbH, Spangenberg,
Germany). The animals were frequently checked for automu-
tilation and anti-bite spray (Alvetra GmbH, Neumünster,
Germany) was applied to the paws or a rat collar (Kent
Scientific Corporation,Torrington,CT)usedfor 1 to2 days, if
necessary. In the following 3 to 10 weeks, Static Sciatic Index
(SSI) measurements, as well as the pinch test, were conducted
weekly.
Visualization of Drug Distribution by Vital Dye Staining
To asses the distribution of drug delivery in the sciatic nerve
crush model, we injected 40 μL of toluidine blue vital dye (1%
toluidine blue in 1% Na2B4O7 in distilled H2O) into 5
additional animals. As shown in Fig. 2a and c, the vital dye
was distributed along the mean distances of 10 mm into
proximal and 6 mm into distal direction from the crush injury
and injection sites. The dye was still visible 24 h after
injection (Fig. 2b and d). The nerve tissue was then removed,
fixed by immersion in 4% paraformaldehyde in 0.1 M
phosphate buffer (pH 7.4) overnight in the dark, and freeze
protected by immersion in 30% sucrose for 24 h in the dark
(+4°C). The tissue was then frozen in Tissue-Tek (O.C.T.
Compound; Sakura Finetek, Staufen, Germany) and cut into
longitudinal 10-μm thick serial cryostat sections. The sections
were mounted on uncoated glass slides and demonstrated that
the dye was not only distributed subepineurially, but also in
the center of the nerves (Fig. 2e and f).
Evaluation of Motor Recovery
SSI
Functional motor recovery was evaluated for a period of
3 weeks after sciatic nerve crush injury and for as much as
10 weeks after nerve autotransplantation. Only animals
with no signs of automutilation were evaluated, and those
with slightly reddened toe tips after nail biting were
excluded from behavioral tests for 1 or 2 tests. Eventually
changes occured in numbers of evaluated animals per group
(“see Results for details”). The observers were blinded to
Fig. 1. Schematic drawing of
the sciatic nerve injury and
repair models used in the pre-
sented study. (a) After sciatic
nerve crush, 1 of 6 different
solutions was injected into the
crush lesion through an
epineurial window, which was
closed afterward by a single
epineurial suture. (b) After
bridging a 10-mm sciatic nerve
gap with an autotransplant,
either vehicle alone or
8 nmol/kg C3
156-181 was
injected into each suture site.
PBS=phosphate buffered saline
C3 Peptide in Peripheral Regeneration 187the treatment conditions. After surgery, all animals were
numbered consecutively by the operator (K.H.T.) and the
animal code was only opened after all measurements were
performed and analyzed for each animal.
To evaluate sciatic nerve recovery, toe spread analysis
was carried out weekly after surgery. The animals were
placed into a Plexiglas box (20 cm x 12 cm x 9 cm, special
fabrication Hannover Medical School central research
workshops), which restricted their movements within the
camera’s field of view. The Plexiglas box was fixed on a
glass table (Microsoft, Unterschleißheim, Germany). A
webcam connected to a notebook was placed under the
table. Images of the plantar surface of the animal’s paws
were then acquired and exported to a freely available image
editing program (AxioVision Rel. 4.8; Zeiss, Jena, Ger-
many) for measuring [26]. The parameters of toe spread
(distance toe 1–5) and intermediate toe spread (distance toe
2–4) of the operated hind paws(OTS, OITS) and the non-
operated hind paws (NTS, NITS) were measured. Then the
SSI was calculated by using the following equation (toe
spread factor [TSF]; intermediate toe spread factor [ITSF]).
TSF ¼ OTS   NTS ðÞ =NTS; ITSF ¼ OITS   NITS ðÞ =NITS
SSI ¼ð 108:44   TSFÞþð 31:85   ITSFÞ 5:49:
In healthy animals, the SSI is approximately 0 and
decreases to −100 after complete impairment of the sciatic
nerve.
Electrodiagnostic Measurements
At the end of the observation time, functional reinnervation
of the gastrocnemius muscle was analyzed prior to tissue
explantation. Therefore, ipsilateral and contralateral sciatic
nerves were exposed and electrically shielded on both sides
against the surrounding tissue using latex patches. A bipolar
hook steel electrode was contacted with the nerve proximal
and distal to the suture sites, respectively. Single rectangular
stimuli of 0.1-ms duration were pulsed by a software-
controlled stimulus generator (2-channel Keypoint Portable
EMG-System, Keypoint GmbH, Düsseldorf, Germany). The
stimulus intensity was gradually raised from the threshold of
a minimum response to a level of 30% greater than the
maximum response (not greater than 8 mA). To determine
threshold current intensities, current intensity was raised from
0 mA in gradual steps of 0.1 mA (0–2 mA) or 0.2 mA (2 mA
and greater), and in parallel elicited compound muscle action
potentials (CMAPs) were recorded from the gastrocnemius
muscle (bipolar electromyography needle electrodes inserted
into the tendon and the belly) and were depicted on the screen
of a notebook connected to the Keypoint Portable EMG-
System (Keypoint GmbH). CMAPs or evoked hind-paw
movements were ranked as signs for successful reinnervation.
The term “evoked hind-paw movements” describes the
spreading of the lateral toes of a hind-paw on direct
electrodiagnostical nerve stimulation [21, 25]. The move-
ment also includes the gastrocnemius muscle, which
Fig. 2. Results after injection of
toluidine vital dye into the crush
lesion. Photographs were taken
directly (a) and (c) and 24 h (b)
and (d) after injection of 40 μL
of toluidine blue in 2 different
nerves. The thin suture marks
the closed epineurial window.
(a-d) Scale bar=5 mm.
(e, f) 10-μm longitudinal
cryosections through a third
sample revealed that the vital
dye was distributed also inside
the nerve approximately 10-mm
proximal to the injection site
188 Huelsenbeck et al.potentially initiated backward movement of the hind paw,
together with toe spreading movements. The different
strength of the evocable movements was ranked using a
3-step score system (score 1=twitching of gastrocnemius
muscle with no visible movement of the paw or toes; score
2=twitching of gastrocnemius muscle plus slight movement
of the paw or toes; and score 3=strong movements).
Furthermore, whenever CMAPs could be recorded,
threshold current intensities, as well as maximal CMAP
amplitudes, their latencies and current were determined,
and the motor nerve conduction velocity was calculated.
Electrodiagnostical measurements of the contralateral non-
operated sciatic nerve served as an internal reference.
Gastrocnemius Muscle Weight Ratio
After electrodiagnostical evaluation the gastrocnemius
muscle, together with the adjacent soleus muscle, was
dissected, and the weight was determined for both the leg
ipsilateral and the leg contralateral to the injury. The
gastrocnemius muscle weight ratio (g)ipsilateral divided
by (g)contralateral indicates the value of recovered muscle
mass due to reinnervation by motor axons.
Nerve Morphometry
On explantation, the regenerated nerve tissue was trans-
ected at 4-mm distal to the crush lesion or 1-mm distal to
the distal nerve suture, respectively. The sutures closing the
epineurial window at the crush lesion site or those
connecting the distal nerve stumps to the autotransplant
were still visible as landmarks. The regenerated nerve tissue
was transferred in a fixative according to Karnovsky (2%
paraformaldehyde, 2.5%glutaraldehyde in 0.2 M sodium
cacodylate buffer, pH 7.3 [18, 20] for 24 h, then rinsed 3
times with 0.1 M sodium cacodylate buffer containing 7.5%
sucrose prior to postfixation in 1% OsO4 for 1.5 h). Myelin
staining was performed as previously described [18, 20],
24 h in 1%potassium dichromate, followed by 24 h in 25%
ethanol, and for another 24 h in hematoxylin (0.5 in 70%
ethanol). After dehydration, the tissue was epon-embedded
and semi-thin (1-μm) cross sections were cut with glass
knives (Ultramikrotome System, 2128 Ultrotome; LKB,
Bromma, Sweden) mounted on uncoated glass slides and
stained with toluidine blue to further enhance the myelin
staining [18, 20].
Regenerated myelinated axons (mAx) were analyzed at
defined points of the regenerated nerve tissue (“see Results
for details”). The semi-thin cross sections were digitalized
using an Olympus BX60 microscope (Olympus, Hamburg,
Germany) at 40x magnification at 1288 x 966 DPI, aligning
single pictures to total cross sections using Cell^P (multiple
image alignment, Olympus, Hamburg, Germany), and
finally analyzed using AnalySISPro 3.1/3.2 (Soft Imaging
System GmbH, Hamburg, Germany) [20, 27].
Because of the large size of the cross sections, the
number of mAx was determined only in defined parts of the
entire cross sections [25, 28], followed by measuring the
cross-sectional area and extrapolation to the total number of
mAx. The number of mAx was set in relation to the whole
cross-sectional area to calculate the nerve fiber density
(mAx/mm²). The g-ratio, an index for the grade of axon
myelination, which is determined by the axon diameter
divided by the total fiber diameter, was evaluated for at
least 200 mAx of each section [20, 27] by an indirect
calculation using the following formula: g-ratio=axonal
diameter of myelinated fibers/(axonal diameter of myelinated
fibers+2x myelin thickness).
All quantification was done by an observer blinded to
the experimental conditions. Blinding was achieved by
consecutive numbering of each nerve sample. Numbers
were different to animal numbers used before and given by
persons different from the operator and observers. The
number code was only opened after histomorphometrical
analysis was completed for all samples.
Detection of Active RhoA within the Sciatic Nerves
by Immunoprecipitation
To assess a RhoA inactivation induced by C3
156-181 peptide
solution or C3
bot-wild-type protein within the lesioned and
treated rat sciatic nerve, we performed crush lesion and
injection of 40 μL solution in 12 additional animals. The
injected solutions were as follows: PBS (n=4), 8 nmol/kg
body weight C3
156-181 peptide (n=4) or 8 nmol/kg body
weight C3
bot-wild-type protein (n=4). The highest level of
activated RhoA in the sciatic nerve has been detected before
at 3 days after surgery [29] ,t h e r e f o r ew ec h o s et h es a m e
timeframe for this additional experiment. Three days after
surgery, the animals were sacrificed and 2 cm of the sciatic
nerves rapidly dissected, dried-frozen in liquid nitrogen, and
stored at −80°C. The 2-cm samples were cut out proximal to
the crush lesion (marked by a suture) from the left nerves, and
accordingly from the contralateral noninjured nerves as well.
For immunoprecipitation, samples were pooled from 4
animals/condition and sonicated in 1 mL immunoprecipita-
tion buffer (20 mM Tris HCl pH 7.2, 50 mM NaCl, 3 mM
MgCl, 1%NP40, 100 μM phenylmethylsulfonylfluorid
(PMSF), 1%protease inhibitors) on ice. Solubilized tissue
was spun down at 13,000g for 10 minutes at 4°C.
Immunoprecipitation of GTP-RhoA (guanosin-5'-triphos-
phat bound RhoA) was done for 45 minutes in 4°C using
1 μL antibody (NewEast Biosiences, Malvern, PA, USA),
followed by incubation with 50 μL protein A/G PLUS-
agarose beads (Santa Cruz Biotechnology, Heidelberg,
Germany) for 45 minutes. Agarose beads were spun down
C3 Peptide in Peripheral Regeneration 189at 10,000g for 5 minutes, washed 2 times with immuno-
precipitation buffer and re-suspended in SDS-PAGE sample
buffer. Beads Proteins were separated by SDS-PAGE
(sodium dodecyl sulfate polyarylamide gel electrophoresis)
(15% acrylamide) followed by Western blot analysis with
mouse anti-RhoA (1:200; Santa Cruz Biotechnology).
Finally, all signals were analyzed densitometrically using
the Kodak 1D Image Analysis Software (Eastman Kodak
Company, Stuttgart, Germany) and normalized to β-actin
signals.
Statistical Analysis
For statistical analysis, GraphPad InStat Software, version
3.06 for Windows (GraphPad Software Inc., San Diego,
CA) was used. Data from different groups were compared
pair-wise. This was done with the unpaired t-test for data
that passed the normality test, and the nonparametric Mann-
Whitney U test was chosen for data that did not pass the
normality test (“see Results for details”).
For the autotransplant experiments, the 1-tailed p value
was calculated for analyzing the straightforward hypothesis
that C3
156-181 would support axonal and functional nerve
regeneration in comparison to PBS. The χ
2 distribution
(percentage of animals/group) of values above the median
of the control group (PBS) was analyzed where single
values indicated a difference between the control group and
the group that was treated with C3
156-181. The pvalues with
p<0.05 were taken as statistically significant. The respec-
tive statistical test used is indicated in the result section.
Results
Treatment with C3
156-181 Speeds up Motor Recovery
after Nerve Crush Injury
To assess the motor nerve regeneration after crush injury, the
SSI was calculated weekly. First significant differences in the
SSI were detected 2 weeks after surgery (Mann-Whitney U
test; p<0.05) between the vehicle alone group (PBS) and the
high dosage C3
156-181 group (40 nmol/kg), see Fig. 3a.A t
3 weeks after surgery, SSI values did significantly increase in
comparison to the 2 weeks values in the NGF reference
group as well as all C3
156-181 groups (1.6 nmol/kg, 8 nmol/
kg, 40 nmol/kg). Furthermore, in comparison to the PBS
group value, the SSI values of the 8 nmol/kg C3
156-181 group
and the 40 nmol/kg C3
156-181 group were significantly
increased (Mann-Whitney U test). All results of the SSI
calculation from 1 week before surgery to 3 weeks after
surgery and the gastrocnemius muscle weight ratios are listed
in Table 1.
Fig. 3. Analysis of motor
recovery after nerve crush
injury, as evaluated by the Static
Sciatic Index (SSI) and
calculation of the gastrocnemius
muscle weight ratio. (a) Mean±
SEM values of the SSI
determined 2 weeks and
3 weeks after surgery. A
significant difference to the
phosphate buffered saline (PBS)
control group is seen at first in
the 40 nmol/kg C3
156-181 group
2 weeks after surgery. Best
motor recovery is indicated in
the C3
156-181-treated groups at
3 weeks after surgery. (b) The
mean±SEM value of the
gastrocnemius muscle weight
ratio is correlated to the motor
recovery level determined by the
SSI. Treatment with 8.0 nmol/kg
and 40 nmol/kg C3
156-181
significantly improved the
obtained regeneration values.
NGF=nerve growth factor
190 Huelsenbeck et al.Figure 3b illustratesthat themotor recoverylevel,indicated
by the SSI, did correlate to the gastrocnemius muscle weight
ratio ([g]ipsilateral/[g]contralateral) determined 3 weeks after
surgery. The muscle weight ratios of the 8.0 nmol/kg C3
156-181
group and the 40 nmol/kg C3
156-181 group were significantly
higher than in the PBS group.
Three weeks after surgery electrodiagnostical evaluation
was performed in all groups. The results of the electro-
diagnostical evaluation are summarized in Table 2. The
ipsilateral mean threshold current intensities, the ipsilateral
mean latencies of the maximal evocable CMAPs, as well as
the mean maximal CMAP amplitudes differed significantly
to the values obtained from the contralateral healthy control
nerves (p<0.001-0.05, Mann-Whitney U test). Although no
statistically significant differences were detectable be-
tween the experimental groups, it is noteworthy that the
Table 1. Study I – Crush Injury*
Study I – crush Experimental group
PBS NGF C3
bot (wt) C3
156-181 C3
156-181 C3
156-181
Reference 1 Reference 2 8.0 nmol/kg 1.6 nmol/kg 8.0 nmol/kg 40 nmol/kg
Static sciatic index pre- surgery −1.84±2.36 −3.42±2.13 −2.75±7.95 −11.02±4.07 −7.18±3.58 −10.35±3.90
n=8 n=7 n=8 n=7 n=8 n=8
1-week postsurgery −103.20±1.80 −103.82±3.12 −100.07±2.83 −98.87±3.10 −105.50±1.64 −98.58±2.10
n=8 n=7 n=8 n=7 n=8 n=8
2-weeks postsurgery −106.68±1.71 −106.02±1.65 −102.19±2.40 −104.03±2.59 −106.43±1.95 −101.06±2.22
†
n=8 n=7 n=8 n=7 n=8 n=8
3-weeks postsurgery −80.55±9.87 −66.46±10.94 −77.82±14.60 −55.69±9.75 −55.66±6.38
† −42.05±4.27
‡
n=7 n=7
§ n=8 n=7
¶ n=8
¶ n=8
¶
Gastrocnemius muscle weight ratio 0.47±0.02 0.52±0.02 0.48±0.035 0.51±0.02 0.54±0.01
† 0.55±0.03
†
3-weeks postsurgery n=8 n=7 n=8 n=7 n=8 n=8
n number of animals tested; NGF nerve growth factor; PBS phosphate buffered saline
*Results from analyses of motor behavior, as determined by the Static Sciatic Index and by calculating the gastrocnemius muscle weight ratio.
Data are presented as mean±SEM. Statistical analysis was done by using the Mann-Whitney U test
†p<0.05
‡p<0.01 indicating significant differences between the phosphate buffered saline group values and the C3
156-181 group values evaluated at the
same time after injury
§p<0.05
¶p<0.001 indicating significant inter-week differences (2-weeks values vs 3-weeks values) within one group of animals
Table 2. Study I – Crush Injury*
Current intensity (mA) Maximal CMAP
Threshold Maximal Latency (ms) Amplitude (mV)
Contralateral All (n=36) 0.11±0.01
† 0.76±0.14 1.64±0.06
‡ 55.74±1.98
‡
Ipsilateral PBS (n=4) 0.38±0.11 0.95±0.69 5.3±0.31 4.73±1.29
NGF (n=6) 0.22±0.04 1.0±0.45 4.88±0.84 4.40±0.77
C3bot (wt) (n=4) 0.3±0.11 1.38±0.55 4.63±0.48 5.58±0.80
C3
156-181 1.6 nmol/kg (n=6) 0.27±0.07 1.62±0.37 5.3±0.46 4.27±0.68
C3
156-181 8.0 nmol/kg (n=8) 0.26±0.06 0.84±0.26 5.51±0.22 5.64±0.35
C3
156-181 40 nmol/kg (n=8) 0.21±0.04 0.73±0.28 4.88±0.28 4.90±0.72
CMAP compound muscle action potential; n number of animals tested
*Current intensity, latency and amplitude (mean±SEM) for the threshold and maximal CMAP at the day of explantation, 3 weeks after crush
injury. Statistical analysis was done by using the Mann-Whitney U test
†p<0.05
‡p<0.001 indicating significant differences between contralateral control values and ipsilateral values of all groups investigated
C3 Peptide in Peripheral Regeneration 19140 nmol/kg C3
156-181group had the lowest mean threshold
current intensity as well as the lowest mean current intensity
needed to elicit the maximal CMAP amplitude.
Treatment with C3
156-181 after Nerve Crush Injury Increases
Regeneration of Myelinated Axons in a Dose-Independent
Way
Semi-thin nerve cross sections, harvested 4 mm distal to the
crush lesion 3 weeks after surgery, were morphometrically
analyzed. As depicted in Fig. 4a, the nerve fiber density
differed significantly (unpaired t-test, Welch corrected)
between several groups. In the C3
156-181 treated groups
axonal regeneration was significantly increased in compar-
ison to the PBS group. Furthermore, in the 1.6 nmol/
kg C3
156-181 group and the 8.0 nmol/kg C3
156-181 group,
significantly more myelinated axons per mm
2 regenerated
than in the NGF and the C3
bot (wt) reference groups. It is
noteworthy that the highest nerve fiber density was detected
in the group treated with only 1.6 nmol/kg C3
156-181.
Representative photomicrographs of nerve cross sections
are presented in Fig. 4 for PBS (Fig. 4b) and 1.6 nmol/
kg C3
156-181 (Fig. 4c) treated animals. Although in all
sections signs of axonal degeneration (onion bulb forma-
tions) were still visible 4 mm distal to the crush at 3 weeks
after surgery, the different degree of regeneration of
myelinated axons was evident. More results from the
morphometrical analysis of semi-thin nerve cross sections
harvested 4-mm distal to the crush lesion 3 weeks after
surgery are summarized in Table 3.
Beside the nerve fiber density no other analyzed parameter
differed significantly between the groups. A tendency
however, to increased axonal diameters in the C3
156-181
treated groups appeared in comparison to the other con-
ditions (highest value in the 40 nmol/kg-C3
156-181group).
Treatment with 8.0 nmol/kg C3
156-181 after 10-mm Nerve
Autotransplantation Speeds Up Reinnervation
of Hind-Limb Muscles and Increases Motor Function
While after 10-mm nerve autotransplantation the evaluation
of the SSI demonstrated almost no recovery and no
differences between the analyzed conditions, significant
differences could be detected with other test paradigms.
Fig. 4. Nerve fiber densities as
determined by nerve
morphometry 4-mm distal to the
crush lesion at 3 weeks after
surgery. (a) Bar graph depicting
the number of regenerated
myelinated axons/mm
2.
Treatment with C3
156-181
significantly increased axonal
regeneration. (b) and (c) Details
of semi-thin cross section
through regenerated nerves after
phosphate buffered saline (PBS)
(b), or 1.6 nmol/kg C3
156-181
(c) treatment. Arrowheads point
to onion bulb formations of
degenerated axons that are still
present. Scale bar=20 μm.
NGF=nerve growth factor
192 Huelsenbeck et al.During the Early Phase of Regeneration (4 weeks) C3
156-181
Promotes Axonal Elongation into Motor Targets
and Reduces Axonal Sprouting
During the 4-week observation period the size of the
regenerating gastrocnemius muscle did not increase to values
allowing recording of CMAPs. However, electrical stimula-
tion of the regenerated nerve proximal to the autotransplant
did result in visible movements evoked by the stimulation
suchastwitchingofthegastrocnemiusmuscle(score1)orasa
progression backward movement of the paw or toe
spreading movements (score 2). Very strong movements
or combined movements were given a score 3 value. A
score of 0 indicated no evocable movement. As depicted
in Fig. 5a treatment with C3
156-181 resulted in evocable
movements with higher scores than treatment with PBS
vehicle alone. Figure 5b illustrates the results of calculat-
ing the gastrocnemius muscle weight ratio ([g]ipsilateral/
[g]contralateral) 4 weeks after surgery. Significantly more
animals of the C3
156-181 group displayed muscle weight
ratios above the median of the PBS control group (0.325,
χ
2 distribution of animals per group [%]).
As depicted in Fig. 5c, calculation of the nerve fiber
density at 1-mm distal to the autotransplant revealed, during
the first 4 weeks after surgery, that significantly less
myelinated axons per mm
2 regenerated in the C3
156-181
group than in the PBS group (χ
2 distribution of animals per
group [%] with values greater than the median of the PBS
control group). No other morphometrical differences could
be detected 4 weeks after surgery. Complete results from
the morphometrical analysis of semi-thin nerve cross
sections harvested 4 or 10 weeks after surgery are
summarized in Table 4.
Treatment with 8.0 nmol/kg C3
156-181 Increases Nerve
Functionality 10 Weeks after 10-mm Nerve
Autotransplantation
During a period of 10 weeks after autotransplantation, the
gastrocnemius muscle mass did increase to a size allowing
electrodiagnostical evaluation of the regeneration status.
The results of the electrodiagnostical evaluation are
summarized in Table 5.
Tenweeksaftersurgerybothgroupsdifferedsignificantlyin
their ipsilateral maximal current intensity, the latency of the
maximal evocable compound muscle action potential
(CMAP), as well as the maximal CMAP amplitude to the
values obtained from the contralateral healthy control nerves
(Mann-Whitney U test, 2-tailed p value). There were no
intergroup differences detectable, except the following.
Calculation of the 1-tailed p value following the hypothesis
that C3
156-181 treatment promotes motor recovery detected a
significantly (p<0.05) higher mean maximal CMAP ampli-
tude in the C3
156-181 group (22.68±2.76 mA) in comparison
to the PBS control group (16.68±1.61 mA). Analyzing the
χ
2-distribution of animals per group (percentage), which
Table 3. Study I – Crush Injury*
Study I – crush Experimental group
PBS NGF C3
bot (wt) C3
156-181 C3
156-181 C3
156-181
Reference 1 Reference 2 8.0 nmol/kg 1.6 nmol/kg 8.0 nmol/kg 40 nmol/kg
Myelinated axons/mm
2 3887±1036 6393±956 4714±1434 9412±836 9071±617 7492±689
n=7 n=5 n=8 n=7 n=8 n=6
†vs NGF+C3
bot †vs NGF
†vs PBS
‡vs PBS
‡vs PBS
Axonal area 3.17±0.13 μm
2 3.61±0.42 μm
2 3.43±0.33 μm
2 3.70±0.39 μm
2 3.44±0.21 μm
2 3.66±0.42 μm
2
n=6 n=4 n=7 n=7 n=7 n=5
Axonal diameter 2.87±0.11 μm 2.98±0.12 μm 2.72±0.15 μm 3.10±0.12 μm 3.11±0.05 μm 3.13±0.08 μm
Myelin thickness 0.88±0.07 μm 0.77±0.11 μm 0.85±0.07 μm 0.91±0.05 μm 0.90±0.05 μm 0.85±0.09 μm
n=3 n=4 n=6 n=5 n=4 n=4
g Ratio 0.51±0.03 0.59±0.04 0.50±0.02 0.51±0.01 0.50±0.01 0.55±0.03
n number of animals tested; NGF nerve growth factor; PBS phosphate buffered saline
*Results of the morphometrical analysis of regenerated myelinated axons 4-mm distal of the crush lesion at 3-weeks postsurgery. Data are
presented as mean±SEM. Statistical analysis was done with the unpaired t test after Welch correction
†p<0.05
‡p<0.01 indicating significant differences between the groups as listed
C3 Peptide in Peripheral Regeneration 193displayed a motor nerve conduction velocity ratio greater than
the median value of the PBS control group (0.51), further
indicated significantly better motor nerve function in the
C3
156-181 group (Fig. 6a). The gastrocnemius muscle weight
ratio was 10 weeks after autotransplantation no longer
different between the PBS control group (0.50±0.07) and
the C3
156-181 group (0.49±0.08).
Increased Nerve Functionality after Treatment with C3
156-181
is Related to Increased Axonal Diameters and Myelin
Thickness
Again, the regenerated nerve tissue was morphometrically
analyzed 1-mm distal to the autotransplant (see Table 5).
The groups were statistically compared with regard to the
χ
2 distribution of animals per group (percentage), with
values greater than the median of the PBS control group.
Ten weeks after autotransplantation, the number of
regenerated myelinated axons per mm
2 was no longer
different between the groups. Additionally, the axonal area
was similar in both groups. However, axonal diameter (Fig. 6b)
and myelin thickness (Fig. 6c) showed significant differences
in the χ
2 distribution, indicating increased axonal maturation
10 weeks after treatment with 8 nmol/kg C3
156-181.T h eg-
ratio was similar in both groups, demonstrating that the
regenerated myelinated axons displayed a myelin thickness
appropriate to their diameter.
C3
156-181 Peptide Modulates Active RhoA Levels in Vivo
To elucidate the activity of the C3
156-181 peptide in vivo,
active RhoA levels have been measured in an immunopre-
cipitation experiment in the proximal sciatic nerve. It has
been demonstrated before that a lesion of rat sciatic nerves
results in RhoA activation proximal to the lesion sites [29].
Figure 7 illustrates that treatment with C3
156-181 and C3
bot
wt peptide prevented this activation in comparison to the
treatment with PBS alone. The lower level in Fig. 7a gives
the input of β-actin and the middle level the input of RhoA
into the Western blot experiment; the upper level gives the
active GTP-RhoA.Figure 7b depicts the ratio between total
RhoA input and activated GTP-RhoA levels (both normal-
ized against β-actin). Three days after crush lesion and
treatment with PBS, C3
156-181 peptide (8 nmol/kg), or
C3
bot-wild-type protein (8 nmol/kg), the levels of active
GTP-RhoA were clearly reduced in ipsilateral and contra-
lateral sciatic nerve samples from the C3
156-181 peptide and
C3
bot-wild-type protein-treated groups in comparison to the
PBS-treated group.
Discussion
This study provides the first evidence that a single
administration of the short C3
bot-derived 26 amino-acid
fragment C3
156-181 is sufficient to promote peripheral nerve
regeneration after injury of different severity by enhancing
axonal elongation into appropriate targets followed by
Fig. 5. Analysis of regeneration parameters 4 weeks after 10-mm nerve
autotransplantation. (a) Bar graph depicting a significant right shift of
the evocable movement score after treatment with C3
156-181.( b)F o u r
weeks after surgery, significantly more animals of the C3
156-181 group,
as in the phosphate buffered saline (PBS) group displayed a
gastrocnemius muscle weight ratio greater than the control group
median. (c) The density of regenerated myelinated axons at 1-mm distal
to the autotransplants at 4 weeks after surgery was significantly reduced
after C3
156-181 treatment
194 Huelsenbeck et al.increased axonal maturation, which results in fast and
substantial functional motor recovery.
Support of Axonal Elongation and Maturation Instead
of Sprouting by C3
156-181
The axonotrophically active region of the clostridial C3
bot
wild-type protein has been identified to be localized within
the amino acids 154–182 of C3
bot [30]. The 29 amino-acid
fragment C3
154-182 promoted axonal outgrowth from
organotypic hippocampal slice cultures into entorhinal slice
cultures [30] in vitro. Furthermore, C3
154-182 has recently
been shown to increase axonal outgrowth across spinal cord
injuries and to improve functional recovery after such
injuries [24]. The enzymatic RhoA inactivation by the ADP
(adenosindiphosphat)-ribosyltransferaseactivityofC3
bot wild-
type protein is long known [31], but it has also been shown
before that enzyme-deficient C3
bot mutants (C3
botE174A,
C3
botE174Q) are equally efficient in stimulating axonal
outgrowth from hippocampal neuron cultures [32]. Although
the C3
154-182 region does not posses enzymatic activity, a
RhoA inactivating function mediated via an (as yet) unknown
mechanism could not be fully excluded until now, and RhoA
is known to be crucially involved in actin and microtubule
dynamics [24]. Pull-down experiments have shown a
reduction of active RhoA levels in primary cultures of
embryonic hippocampal neurons in vitro after incubation
with C3
154-182 for 4 days. We used the further shortened
26 amino acid fragment C3
156-181 in the current study, which
showed the same effects as the longer 29 amino acid peptide
in vitro.
We attribute the effect of C3
156-181 on axonal elongation
and maturation presented here to the residual RhoA
inactivation. After injury, an up-regulation of activated RhoA
is detected in the axons within the proximal nerve [29]. It has
further been postulated that this RhoA activation accounts as
a pause signal for axonal outgrowth [33]. As such the RhoA
inactivation is eventually the basis for the so-called staggered
outgrowth of regenerating axons for a period of as much as
10 weeks after injury, in which regenerating neurons
Table 4. Study II – Nerve Autotransplant*
Study II Nerve autotransplant Experimental group
PBS - 4 weeks
Reference
C3
156-181 - 4 weeks
8.0 nmol/kg
PBS - 10 weeks
Reference
C3
156-181 - 10 weeks
8.0 nmol/kg
Myelinated axons/ mm
2 n=10 n=10 n=10 n=10
1533±196 1420±320 14,021±1108 14,797±983
Axonal area 2.95±0.30 μm
2 3.88±0.60 μm
2 4.62±0.18 μm
2 4.76±0.20 μm
2
Axonal diameter 2.24±0.10 μm 2.45±0.16 μm 2.74±0.07 μm 2.73±0.14 μm
Myelin thickness n=5 n=5 n=10 n=7
0.65±0.02 μm 0.63±0.04 μm 0.72±0.04 μm 0.78±0.04 μm
g ratio n=5 n=5 n=10 n=10
0.66±0.004 0.68±0.02 0.64±0.02 0.64±0.02
n number of animals tested; PBS phosphate buffered saline
*Results of the morphometrical analysis of regenerated myelinated axons 1-mm distal to an autotransplant at 4 weeks and 10 weeks postsurgery.
Data are presented as mean±SEM
Table 5. Study II – Nerve Autotransplant
Current intensity (mA) Maximal CMAP
Threshold Maximal Latency (ms) Amplitude (mV)
Contralateral All (n=19) 0.35±0.24 0.67±0.22
† 2.33±0.23
† 52.22±4.69
†
Ipsilateral PBS 10 weeks (n=10) 0.63±0.5 1.87±0.32 3.42±0.28 16.68±1.61
C3
156-181 8.0 nmol/kg 10 weeks (n=9) 0.78±0.32 1.73±0.4 3.27±0.33 22.68±2.76
‡
n number of animals tested; CMAP compound muscle action potential
*Current intensity, latency, and amplitude (mean±SEM) for the threshold and maximal CMAP at the day of explantation, 10 weeks after nerve
autotransplantation. Statistical analysis was done with the Mann-Whitney U test
†p<0.01 indicating significant differences between contralateral control values and ipsilateral values of all groups investigated
‡p<0.05 indicating the calculation of a 1-tailed p value revealed statistical differences between PBS- and C3
156-181-values
C3 Peptide in Peripheral Regeneration 195subsequently start to re-grow their axons [33, 34]. Staggered
axonal outgrowth reduces the chance for timely and full
recovery after severe peripheral nerve injury. Treatment of
sciatic nerve crush injuries in mice with the synthetic Rho-
kinase inhibitor fasudil (HA-1077) facilitated the maturation
of regenerating myelinated axons, as indicated by increased
mean fiber diameters and decreased regenerating fiber
densities [33]. The same effect is seen in the current study
after treatment with C3
156-181.
Possible Mechanism Underlying the Increased Motor
Recovery Induced by C3
156-181
It has further been shown that RhoA is activated after
peripheral nerve injury in motor neurons and dorsal root
ganglia, but not in Schwann cells [29, 33]. A significant
increase of CMAP amplitudes indicative for better motor
recovery was seen in fasudil treated mice after crush injury
[33]. Treatment with C3
156-181 also resulted in improved
motor recovery. Our results, together with the shown
enzyme-independent inactivation of RhoA by C3
154-182
Fig. 6. Analysis of regeneration parameters at 10 weeks after 10-mm
nerve autotransplantation. (a) 10 weeks after surgery significantly
more animals of the C3
156-181 group, as in the phosphate buffered
saline (PBS) group displayed a motor nerve conduction velocity ratio
greater than the control group median. (b) and (c) Nerve morphometry
at 1-mm distal to the autotransplants 10 weeks after surgery. Treatment
with 8.0 nmol/kg C3
156-181 significantly increased axonal diameters
(b) and myelin thickness (c) of the regenerated myelinated axons
Fig. 7. Prevention of RhoA activation in vivo by C3
156-181 peptide or
C3
bot-wild-type protein. (a) GTP-RhoA immunoprecipitation and
Western blot analysis demonstrating reduced levels of active GTP-
RhoA in contralateral and ipsilateral sciatic nerves after treatment with
C3
156-181 peptide and C3
bot-wild-type protein in comparison to
phosphate buffered saline (PBS) treatment. (c) Densitometry and
normalization against β-actin allowed the calculation of the ratio
between total RhoA input (middle level) in (b) and GTP-RhoA levels
(upper level) in (b). The bar graph underscores the prevented
activation of RhoA by treatment with C3
156-181 peptide or C3
bot-
wild-type protein in contrast to application of PBS
196 Huelsenbeck et al.[24] makes it likely that a motoneuron specific inactivation
of RhoA underlies the regeneration promoting effects of
C3
156-181 in the current study. Active RhoA in neurons
functions as the antagonist to the inductors of neurite
outgrowth (Rac and Cdc42), and it stops axonal growth and
further induces growth cone collapse [31]. The inactivation
of RhoA by C3
bot catalyzed ADP-ribosylation or by the
Rho-kinase inhibitor fasudil, therefore, supports axonal
outgrowth after central [35] or peripheral nerve injury [29,
33]. In the current study, treatment with C3
156-181 increases
axonal elongation and reconnection to appropriate targets
(functional motor recovery) via a not-yet known pathway.
The fact that 1-time administration is sufficient to enhance
repair, however, indicates an initial beneficial effect of C3
156-
181-peptide based on the inactivation of RhoA.
Advantage of C3
156-181 over C3
bot Wild Type
Stimulation ofaxonaloutgrowth and maturationaccompanied
by accelerated motor recovery has also been demonstrated
before for the treatment of sciatic nerve crush injuries with
NGF by injection of NGF solution into the crush sites [36].
Therefore, treatment with NGF was chosen as a reference
condition in the crush injury model used in the current study,
but treatment with C3
156-181 demonstrated a higher potential
to increase peripheral nerve regeneration. The mode of NGF
action does not involve inactivation of RhoA but a trophic
action on the regenerating neurons mediated via the low-
affinity nerve growth factor receptor [37]. Currently no
receptor for C3 peptides or C3
bot is known, and we can only
speculate with regard to the RhoA inactivation by C3
peptides (e.g., a direct influence on RhoA by the internalized
peptide [24]). The treatment with C3
156-181 showed a higher
potential to increase peripheral nerve regeneration than
treatment with C3
bot-wild-type protein. This indicates that
the action of C3
156-181 is more neuron-specific. Classical
pathways of enzymatic RhoA inactivation, as known for the
C3
bot-wild-type protein, do not selectively act on neurons
and axons, but also do affect central glial cells [38, 39]. The
glial reaction strictly depends on the classical pathway and is
not seen with enzyme-deficient C3
bot mutants or the C3
peptides [39]. In the current study, axonal and functional
regeneration parameters after treatment with C3
bot-wild-type
protein are significantly behind those after treatment with
C3
156-181. This indicates that the treatment with C3
bot-wild-
type protein additionally activates other mechanisms, such as
a central glia reaction, which possibly negatively influences
neuronal regeneration processes. To date an effect on
peripheral glia cells, Schwann cells, has not been demon-
strated and has to be the subject of future studies. However,
the promoting effect of C3
156-181 on peripheral nerve
regeneration could not only be direct, but also indirectly
meditated by Schwann cells. The Schwann cells create a
regeneration-promoting milieu [4, 10] and they might be
influenced by C3
156-181 to do so faster and more successful
than usual.
Conclusion
Our data indicate that C3
156-181 is a possible therapeutic
agent to support functional recovery after peripheral nerve
injury and repair, especially the demonstrated regeneration-
promoting effects, that appeared after a single application,
make a therapeutic use easy to transfer in a clinical setting.
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